（来源：国金证券第5小时） 来源：市场资讯 优势 | 申购价格 | 所属行业 | 发行市盈率 | 行业最近一个月平 | | --- | --- | --- | --- | | | | | 均静态市盈率 | | 17.52元 | 专用设备 制造业 | 不适用 市销率 | 41.36倍 | | | | 19.92倍 | | | 可比公司 | | | | | --- | --- | --- | --- | | 证券简称 | 市盈率(倍) | 市值(亿元) | 近一月涨跌 | | 惠泰医疗 | 44.51 | 342.00 | -0.32% | | --- | --- | --- | --- | | 心脉医疗 | 32.00 | 120.92 | 7.03% | 公司主营业务介绍 公司是一家专注于心血管疾病精准诊疗创新医疗器械研发、生 产和销售的国家高新技术企业,致力于开发为心血管疾病诊疗 带来变革的精准解决方案。 | | | 主要财务数据 | | | --- | --- | --- | --- | | | 2024年 | 2023年 | 2022年 | | 营业收入 | 3.17 | 1.84 | 0.92 | | ...

Group 1 - The capital market in Shenzhen has nurtured a high-quality group of listed companies, with 425 A-share listed companies and 159 overseas listed companies ranked among the top in comprehensive competitive strength [1] - As of August 15, 16 Shenzhen enterprises are in the process of applying for A-share IPOs, indicating a growing trend of technology innovation companies seeking public funding [2][5] - The IPO candidates include 6 companies aiming for the Shenzhen Stock Exchange, 3 for the Shanghai Stock Exchange's Sci-Tech Innovation Board, and 7 for the Beijing Stock Exchange, with 15 already in the inquiry stage [2] Group 2 - Among the IPO candidates, Huike Co., Ltd. stands out with total assets exceeding 100 billion yuan and projected revenue of 40.31 billion yuan in 2024, aiming to enhance its core competitiveness through increased R&D investment [2][4] - Hengyun Chang is noted for its rapid growth, with a compound annual growth rate (CAGR) of 84.91% in revenue and 156.72% in net profit from 2022 to 2024, focusing on semiconductor equipment manufacturing [4] - Many of the 16 companies have substantial orders and are looking to expand capacity or enter global markets, indicating a strong demand for their products [4] Group 3 - Shenzhen's listed companies have a significant focus on R&D, with over 50% of the 425 listed companies in the technology innovation sector, reflecting a trend towards high-quality production capabilities [5] - Companies like Kairui Zhi have invested heavily in R&D, achieving 615.34 million yuan in R&D expenses over three years and holding 247 patents, which strengthens their competitive edge [6] - The average gross margin for companies applying for the Sci-Tech Innovation Board and the Growth Enterprise Market is between 40% and 60%, showcasing their resilience in a changing market [6] Group 4 - The capital market is becoming more inclusive, allowing more "hard tech" companies to access funding, with new listing standards accommodating unprofitable but high-growth firms [7] - Companies like Beixin Life and Dapu Micro are examples of firms with rapid growth despite not being profitable, with Beixin Life's revenue projected to grow from 92.45 million yuan in 2022 to 317 million yuan in 2024 [7] - Dapu Micro focuses on enterprise-level SSD products and has seen its market scale grow rapidly, driven by the demand from artificial intelligence applications [7]

Group 1 - The core viewpoint is that Shenzhen's technology innovation enterprises are seizing development opportunities with 16 companies currently in line for A-share IPOs, which could inject strong momentum into the industry [3][4] - The capital market reforms are enhancing the attractiveness for high-tech and high-growth companies, facilitating financing channels for enterprises at different growth stages [4][10] - Among the 16 companies, 6 are targeting Shenzhen Stock Exchange IPOs, 3 are aiming for Shanghai Stock Exchange's Sci-Tech Innovation Board, and 7 are looking at Beijing Stock Exchange [4] Group 2 - Huike Co., a leading company in the semiconductor display panel industry, has total assets exceeding 100 billion yuan and aims to enhance its core competitiveness through IPO fundraising [4] - Hengrunchang is the fastest-growing company among the 16, with a compound annual growth rate (CAGR) of 84.91% in revenue and 156.72% in net profit from 2022 to 2024 [5] - Many companies are experiencing order surpluses and are looking to expand capacity or target global markets through capital market financing [6] Group 3 - Shenzhen's innovation is highlighted by the fact that over 50% of the 425 listed companies are from the Sci-Tech Innovation Board and Growth Enterprise Market, indicating a concentration of listing resources in new productive forces [7] - The companies in line for IPOs exhibit significant technological innovation, with substantial R&D investments and patent achievements forming competitive advantages [8][9] - Companies like Dapu Micro and Beixin Life have maintained high R&D investment ratios, with 36.15% and 65.5% of their cumulative revenue allocated to R&D over the past three years [9] Group 4 - The capital market is becoming more inclusive, allowing more "hard tech" companies to access funding, including those that are currently unprofitable [10] - Companies like Beixin Life and Dapu Micro are characterized by rapid growth despite not being profitable, with Beixin Life's revenue projected to grow from 92.45 million yuan in 2022 to 317 million yuan in 2024 [11] - Shenzhen is actively cultivating the "20+8" industrial clusters, with emerging companies in sectors like semiconductors, artificial intelligence, humanoid robots, and biomedicine rapidly growing [11]

Core Insights - July 18 marked a significant day for the capital market with multiple key approvals from the China Securities Regulatory Commission (CSRC) [1] - The approvals indicate an acceleration in the review process for quality mergers and acquisitions, as well as a more inclusive approach for IPOs on the Sci-Tech Innovation Board [1][7] Group 1: Mergers and Acquisitions - The CSRC approved China Shipbuilding Industry Company’s absorption merger with China Shipbuilding Heavy Industry Company, marking a significant step in the integration of two major listed platforms under the China Shipbuilding Group [2] - The merger is the first to complete the Shanghai Stock Exchange review and CSRC registration under the new restructuring regulations, setting a precedent for future mergers [2] - ChipLink Integrated Circuit Manufacturing Co. received approval for a significant asset restructuring deal, involving the acquisition of 72.33% of ChipLink Yuezhou Integrated Circuit Manufacturing for a total transaction value of 5.897 billion yuan, despite both companies currently being unprofitable [2][3] Group 2: Initial Public Offerings (IPOs) - Wuhan Heyuan Biotechnology Co. became the first company to receive IPO registration approval under the newly restarted fifth set of standards on the Sci-Tech Innovation Board [4] - Heyuan Biotechnology plans to raise 2.4 billion yuan for the construction of a recombinant human albumin production base, new drug development, and to supplement working capital [5] - Shenzhen Beixin Life Technology Co. also passed the listing review under the new standards, focusing on high-performance innovative medical devices for cardiovascular interventions [5] - Yushu Technology has initiated the IPO counseling process, with plans for a comprehensive evaluation of its listing conditions by October 2025 [5][6]